An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study

Heterogeneity of platelets and their responses

“…Geisen et al. [ 121 ] described progress toward prophylactic treatment with the use of a subcutaneous anti HPA-1a monoclonal antibody (RLYB212), which is intended to drive phagocytosis of fetal-derived HPA-1a antigen in maternal circulation to prevent alloimmunization. At the ISTH Congress, the authors showed elimination of HPA-1a platelets from circulation following treatment with (RLYB212).…”